📊 ENTX Key Takeaways
Is Entera Bio Ltd. (ENTX) a Good Investment?
Entera Bio is a pre-revenue biotech company with minimal commercial traction (42K revenue) and severe cash burn of 5.5M annually in operating activities. With only 8.6M in cash and negative free cash flow of 5.6M, the company has less than 18 months of runway at current burn rates, creating significant going concern risk. The company lacks profitability, positive cash generation, and demonstrated commercial viability.
Entera Bio's fundamentals reflect a pre-commercial biotech profile: negligible revenue, no gross profit, and very large operating and net losses relative to sales. The balance sheet is clean, with strong liquidity, substantial cash relative to liabilities, and no meaningful debt, but the business still depends on improving clinical/commercial execution before the current cash runway is exhausted.
Why Buy Entera Bio Ltd. Stock? ENTX Key Strengths
- Strong liquidity position with 10.83x current ratio providing near-term operational flexibility
- Zero debt/equity ratio eliminates financial leverage risk and debt service obligations
- Substantial stockholders equity of 15.2M relative to liabilities suggests retained capital from financing
- Strong liquidity with current and quick ratios of 10.83x
- Low financial leverage with essentially no long-term debt
- Solid equity base of $15.23M versus only $2.17M in liabilities
ENTX Stock Risks: Entera Bio Ltd. Investment Risks
- Critical cash runway of approximately 18 months at current burn rate with no profitable operations to offset losses
- Negligible revenue generation (42K) demonstrates complete lack of commercial market validation or product adoption
- Persistent operating losses of 8.5M with negative operating margin of -20207% indicates fundamental business model challenges
- Negative free cash flow of 5.6M indicates company is consuming capital faster than it can sustain without additional financing
- Pre-revenue biotech stage with high execution risk and dependence on future drug development success
- Revenue base is immaterial at just $42K, indicating weak current operating scale
- Severe negative profitability with operating income of -$8.49M and net margin around -20055%
- Negative operating cash flow and free cash flow suggest continued cash burn and future funding risk
Key Metrics to Watch
- Quarterly revenue growth and evidence of any commercial traction or clinical progress
- Cash burn rate and remaining cash runway to determine urgency of financing needs
- Operating cash flow trends and any movement toward sustainability
- Progress on pipeline development and clinical trial milestones
- Insider transaction patterns and insider confidence levels
- Quarterly operating cash burn relative to cash balance
- Revenue growth and progress toward sustainable gross profit
Entera Bio Ltd. (ENTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.83x current ratio provides a solid financial cushion.
ENTX Profit Margin, ROE & Profitability Analysis
ENTX vs Healthcare Sector: How Entera Bio Ltd. Compares
How Entera Bio Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Entera Bio Ltd. Stock Overvalued? ENTX Valuation Analysis 2026
Based on fundamental analysis, Entera Bio Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Entera Bio Ltd. Balance Sheet: ENTX Debt, Cash & Liquidity
ENTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Entera Bio Ltd.'s revenue has declined by 68% over the 5-year period, indicating business contraction. The most recent EPS of $0.25 reflects profitable operations.
ENTX Revenue Growth, EPS Growth & YoY Performance
ENTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$3.0M | $0.07 |
| Q2 2025 | N/A | -$2.1M | $0.06 |
| Q1 2025 | N/A | -$2.0M | $0.05 |
| Q3 2024 | N/A | -$2.4M | $0.08 |
| Q2 2024 | N/A | -$2.1M | $0.06 |
| Q3 2023 | N/A | -$2.4M | $0.08 |
| Q2 2023 | N/A | -$2.3M | $0.08 |
| Q1 2023 | N/A | -$2.2M | $0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Entera Bio Ltd. Dividends, Buybacks & Capital Allocation
ENTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Entera Bio Ltd. (CIK: 0001638097)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENTX
What is the AI rating for ENTX?
Entera Bio Ltd. (ENTX) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 89% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENTX's key strengths?
Claude: Strong liquidity position with 10.83x current ratio providing near-term operational flexibility. Zero debt/equity ratio eliminates financial leverage risk and debt service obligations. ChatGPT: Strong liquidity with current and quick ratios of 10.83x. Low financial leverage with essentially no long-term debt.
What are the risks of investing in ENTX?
Claude: Critical cash runway of approximately 18 months at current burn rate with no profitable operations to offset losses. Negligible revenue generation (42K) demonstrates complete lack of commercial market validation or product adoption. ChatGPT: Revenue base is immaterial at just $42K, indicating weak current operating scale. Severe negative profitability with operating income of -$8.49M and net margin around -20055%.
What is ENTX's revenue and growth?
Entera Bio Ltd. reported revenue of $42.0K.
Does ENTX pay dividends?
Entera Bio Ltd. does not currently pay dividends.
Where can I find ENTX SEC filings?
Official SEC filings for Entera Bio Ltd. (CIK: 0001638097) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENTX's EPS?
Entera Bio Ltd. has a diluted EPS of $0.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ENTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Entera Bio Ltd. has a SELL rating with 89% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ENTX stock overvalued or undervalued?
Valuation metrics for ENTX: ROE of -55.3% (sector avg: 15%), net margin of -20,054.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ENTX stock in 2026?
Our dual AI analysis gives Entera Bio Ltd. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ENTX's free cash flow?
Entera Bio Ltd.'s operating cash flow is $-5.5M, with capital expenditures of $80.0K. FCF margin is -13,373.8%.
How does ENTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -20,054.8% (avg: 12%), ROE -55.3% (avg: 15%), current ratio 10.83 (avg: 2).